Lipoxin A5 – 25 µg

Brand:
Cayman
CAS:
110657-98-2
Storage:
-80
UN-No:
De Minimis - 1170 / 3

Lipoxin A5 (LXA5) is produced by enzymatic transformation of EPA by leukocytes.{15471} LXA5 slowly contracts pulmonary parenchymal strips from guinea pig with similar potency to that of LXA4 and LXB4.{15472} However, LXA5 does not exert the vasodilatory effects on aortic smooth muscle exhibited by LXA4 and LXB4.{15472}  

 

Available on backorder

SKU: 10011453 - 25 µg Category:

Description

A 5-series LO derived from EPA; contracts pulmonary parenchymal strips from guinea pig with similar potency to that of LXA4 and LXB4, yet does not exert the vasodilatory effects on aortic smooth muscle exhibited by LXA4 and LXB4


Formal name: 5S,6R,15S-trihydroxy-7E,9E,11Z,13E,17Z-eicosapentaenoic acid

Synonyms:  LXA5

Molecular weight: 350.5

CAS: 110657-98-2

Purity: ≥95%

Formulation: A solution in ethanol


Product Type|Biochemicals|Lipids|Lipoxins/Resolvin Es||Research Area|Immunology & Inflammation|Inflammatory Lipid Mediators|Specialized Pro-Resolving Mediators||Research Area|Immunology & Inflammation|Innate Immunity||Research Area|Lipid Biochemistry|Lipoxygenase Pathways